VAKCINA

boomer crook wrote:

Talason wrote:uopšte nije bitno da li je ovaj ili onaj %

bitno je da svaka vakcina, od ovih koje su u opticaju ima skoro 100% efikasnost kada su u pitanju teži oblici bolesti

to omogućava da se imunitet razvija paralelno, bolest + vakcina, tako da se smanjuje potreba za trećim busterom, što opet vodi ka tome da kovid 19 postane jedna obična sezonska prehlada

da do toga dođe, jedino je potrebno vakcinisati bez milosti

i zato svaki korporativni ili drzavni entitet koji saplice konkurenciju neka jede govna.

The Oxford/AstraZeneca vaccine offers as little as 10% protection against the Covid variant first seen in South Africa, researchers have suggested.

Scientists who conducted a small-scale trial of the vaccine’s efficacy said it showed very little protection against mild to moderate infection, though they expressed hope that – in theory – it would still offer significant protection against more serious infection.

The Pfizer-BioNTech COVID-19 vaccine is shown to neutralize SARS-CoV-2 with the N501Y and E484K mutations, which are present in strains from the UK and South Africa, according to a study in @NatureMedicine. https://t.co/E7VDobsq7n pic.twitter.com/3x5bC5QAFc

— Nature Research (@nresearchnews) February 8, 2021

We engineered three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viruses containing key spike mutations from the newly emerged United Kingdom (UK) and South African (SA) variants: N501Y from UK and SA; 69/70-deletion + N501Y + D614G from UK; and E484K + N501Y + D614G from SA. Neutralization geometric mean titers (GMTs) of 20 BTN162b2 vaccine-elicited human sera against the three mutant viruses were 0.81- to 1.46-fold of the GMTs against parental virus, indicating small effects of these mutations on neutralization by sera elicited by two BNT162b2 doses.

boomer crook wrote:to je seroloska analiza? ne pracenje vakcine kroz populaciju?

lalinea wrote:

boomer crook wrote:to je seroloska analiza? ne pracenje vakcine kroz populaciju?

Da, ohrabrujuca seroloska analiza.
Stvar sa tim seroloskim analizama je sto dok ne znas model za svaki virus-antitela par, ne mozes da znas sta tacno ova analiza znaci u praksi. Npr za grip se to zna iz iskustva, tj istorijskog pracenja, ali za ovaj virus jos uvek to ne znamo. (Pominje se u ovom radu da je ovaj pad daleko od pada koji kod gripa signalizira da je potrebna nova vakcina, ali to je grip a ovo je ovo). Svakako bolja vest nego da se skljokala neutralizacija.

boomer crook wrote:
da li to mozda znaci da je ona juznoafricka studija na malom uzorku ispitanika za AZ omasila? znam da su razlicite vakcine naravno ali onda je mozda ta studija pre-pesimisticna?

boomer crook wrote:znam da nije seroloska. zato i pitam. njihov "nalaz" je bio da AZ ne radi gotovo nista. mislim hocu da kazem da je moguce da im uzorak nije dobar ili da su imali neki drugi proceduralni problem.

boomer crook wrote:in other news: da li je neko dobio poziv za revakcinu?

Why a report on the variants is unhelpful
Just published @NatureMedicine https://t.co/oZemkCN5G8
Looking at virus neutralization of engineered point mutations ignores the extensive gene-gene interactions (the company it keeps),~20 mutations (~10 in spike), for each variant pic.twitter.com/N6QY0mSfS8

— Eric Topol (@EricTopol) February 8, 2021

Pfizer expects to nearly cut in half the amount of time it takes to produce a batch of COVID-19 vaccine from 110 days to an average of 60 as it makes the process more efficient and production is built out, the company told USA TODAY.https://t.co/2mqqW8bWK6

— Corona Information (@Covidinform) February 8, 2021

Preliminary analysis indicates that the UK variant strain that was increasingly prevalent was detected in over 50% of the PCR-confirmed symptomatic cases (32 UK variant, 24 non-variant, 6 unknown). Based on PCR performed on strains from 56 of the 62 cases, efficacy by strain was calculated to be 95.6% against the original COVID-19 strain and 85.6% against the UK variant strain [post hoc].
...
In the South Africa Phase 2b clinical trial, 60% efficacy (95% CI: 19.9 – 80.1) for the prevention of mild, moderate and severe COVID-19 disease was observed in the 94% of the study population that was HIV-negative. Twenty-nine cases were observed in the placebo group and 15 in the vaccine group. One severe case occurred in the placebo group and all other cases were mild or moderate. The clinical trial also achieved its primary efficacy endpoint in the overall trial population, including HIV-positive and HIV-negative subjects (efficacy of 49.4%; 95% CI: 6.1 – 72.8).

This study enrolled over 4,400 patients beginning in August 2020, with COVID-19 cases counted from September through mid-January. During this time, the triple mutant variant, which contains three critical mutations in the receptor binding domain (RBD) and multiple mutations outside the RBD, was widely circulating in South Africa. Preliminary sequencing data is available for 27 of 44 COVID-19 events; of these, 92.6% (25 out of 27 cases) were the South Africa escape variant.